24/7 Market News Snapshot 29 January, 2025 – ImmunityBio, Inc. Common Stock (NASDAQ:IBRX)

January 29, 2025

DENVER, Colo., 29 January, 2025 (247marketnews.com) – (NASDAQ:IBRX) are discussed in this article.
ImmunityBio, Inc. (IBRX) experienced a significant uptick in trading today, commencing at $3.15 and presently valued at $3.295, marking an increase of approximately 6.98% from the previous close of $3.08. This surge in share prices signals a growing bullish sentiment among investors, as highlighted by a robust trading volume of 4.47 million shares. Analysts have identified potential resistance levels around $3.30, with support emerging near $3.15. The stock’s ability to maintain its upward trajectory will likely hinge on surpassing recent highs and sustaining trading volume amid shifting market dynamics.

In a notable development, ImmunityBio has partnered with BeiGene, Ltd. (set to be rebranded as BeOne Medicines, Ltd.) to launch a pivotal confirmatory Phase 3 clinical trial named ResQ201A-NSCLC. This study will investigate the efficacy of combining BeiGene’s tislelizumab, a PD-1 checkpoint inhibitor, with ImmunityBio’s ANKTIVA in patients battling advanced or metastatic non-small cell lung cancer (NSCLC) who have shown resistance to prior immune checkpoint therapies.

The trial’s design draws upon promising results from the QUILT 3.055 trial, which suggested that the synergistic effects of ANKTIVA—a novel IL-15 superagonist—paired with a PD-1 inhibitor could enhance overall survival rates in this difficult-to-treat patient demographic. Previous studies indicate that ANKTIVA has the potential to revitalize T cell activity, which is crucial for forming an effective anti-tumor immune response by increasing the proliferation of natural killer cells as well as CD4+ and CD8+ T cells.

With plans to enroll up to 462 participants across various sites, the collaboration underscores the commitment to addressing the critical needs of NSCLC patients, particularly those with limited treatment options. The primary endpoint of the trial will focus on overall survival, alongside secondary outcomes assessing disease control rates and safety parameters. Dr. Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio, emphasized the urgency of developing effective therapies for patients who have limited options following checkpoint inhibitor treatment. This strategic alliance highlights a pivotal advancement in innovative treatment avenues for metastatic lung cancer patients globally.

Related news for (IBRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.